Background: Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with inflammatory bowel disease [IBD], but the data in paediatrics are limited. We describe the shortterm effectiveness and safety of vedolizumab in a European multi-centre paediatric IBD cohort. 
Conclusions:
Vedolizumab was safe and effective in this cohort of paediatric refractory IBD. These data support previous findings of slow induction rate of vedolizumab in CD and a trend to be less effective compared with patients with UC.
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Background
Vedolizumab is a humanised immunoglobulin G1 monoclonal antibody acting against α4β7 integrin which modulates lymphocyte trafficking specifically to the gut. Results from the GEMINI 1 1 [TNF] treatments were assessed in the induction of remission trial GEMINI 3. In this study, 39% exhibited clinical response by Week 6, but the clinical remission rate did not surpass the placebo arm until 10 weeks [27% vs 12%], suggesting that the effects of vedolizumab on clinical remission may not be evident in the initial weeks of treatment, especially in CD. 3 Subsequent real-life cohort studies in adults support the effectiveness of vedolizumab in inducing and maintaining remission, both in CD and UC. [4] [5] [6] [7] [8] [9] [10] In children, vedolizumab is available off-label and it is typically reserved for patients who have exhausted other treatment options including anti-TNF. Two case series on vedolizumab from North America have recently been published with inconsistent results, one with 52 children 11 and the second with 21 patients. 12 The aim of this multi-centre observational study is to report on the short-and long-term outcomes of vedolizumab therapy in paediatric IBD.
Methods
This retrospective observational study reports the collective experience of vedolizumab in children [2-18 years] from 19 centres affiliated with the Paediatric IBD Porto and with Interest groups of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition [ESPGHAN] , in Europe and Israel. All children were diagnosed with CD, UC or IBD-U by accepted criteria 13 and were commenced on vedolizumab for any reason, combined with any other medications. To avoid selection bias, we included all patients receiving at least one infusion, even if treatment had been discontinued for any reason.
Explicit clinical and demographic data, baseline disease characteristics, previous medications and surgeries, and anthropometric data were recorded 6 months preceding initiation of vedolizumab, at vedolizumab onset and at 6, 14, 22, and 54 weeks thereafter, when available, as well as at last follow-up. The following data were recorded at each time point: disease activity (captured by the weighted Paediatric Crohn's Disease Activity Index [wPCDAI] 
Results

Patient characteristics
A total of 64 children were included with a median follow-up of 24 weeks [IQR 14-38] [ Table 1 ]; 52 [81%] patients were followed for at least 14 weeks, 38 [59%] followed for at least 22 weeks and 10 [16%] followed to at least 1 year. Of the 12 patients with less than 14 weeks' follow-up, 10 ceased vedolizumab and only two lacked sufficient follow-up data.
All children were previously exposed to anti-TNF, 57 [89%] of whom failed intensified dosing regimen and almost half failing a second anti-TNF or third-line therapy [ Table 2 ].
Drug administration
Corticosteroid and nutritional therapy were used as directed by the treating physician, with variable dosing courses as per clinical need. A total of 41 patients [67%] were on corticosteroid therapy at commencement, 12 of whom received high dose induction therapy [above 0.8 mg/ kg]. There was no impact of initial high dose steroid use on Week 14 remission rates in either CD or UC/IBD-U [p = 1.0 and p = 0.89, respectively]. Throughout follow-up there were fewer patients on corticosteroid therapy, with a drop in median dose of steroids over time [ Table 2 ]. 
Secondary outcomes
Univariate analysis showed no association between remission rates and gender, age at diagnosis, disease duration, CRP, presence of perianal disease, or reason for previous anti-TNF failure either in UC/IBD-U or in CD [all p > 0.28; data not shown]. There was no association between remission rates and disease location in CD or disease extent in UC. All CD patients who achieved remission by last follow-up had ileocolonic disease; however, the remission rate of ileocolonic distribution was not significantly different in the smaller cohort with isolated colonic disease There was no demonstrated catch-up growth in the CD patients. The reduced height velocity seen overall before vedolizumab therapy did not improve over the 6 months thereafter (median z-score - In all, 56 children [88%] had a standard induction course with 8-weekly maintenance infusions; eight [12%] commenced 4-weekly infusions from the outset. Of the former, seven [13%] increased dosing to 4-or 6-weekly infusions, due to poor response. Of these, four patients had CD, one of whom subsequently achieved remission, and three had UC, of whom one subsequently achieved remission, another partially responded and the third had no response. There was no difference in success rate between those who commenced on 8-week dosing intervals and those who commenced on 4-week dosing intervals from the outset (20/45 [44%] vs 1/7 [14%] respectively; p = 0.14).
Nineteen children had both baseline and follow-up colonoscopic assessment. Among these children, both UCEIS in UC and SES-CD in CD dropped significantly [ Figure 2 
Safety
No serious drug-related adverse events were reported. Three mild potential drug-related adverse events were recorded: one [13-yearold female] developed otitis externa and periorbital oedema after the first and second infusions, which subsequently resolved and she remained on treatment; the second [17-year-old female] developed an intractable itch after the first infusion and vedolizumab was subsequently ceased; and the third [17-year-old female] developed mild shortness of breath during the fourth infusion, which improved with antihistamine medication and a slower infusion rate. Vedolizumab was continued in this patient, only ceasing later due to poor drug effectiveness.
Discussion
In this largest real-life cohort of vedolizumab use in paediatric IBD to date, we show that vedolizumab is safe and effective in paediatric IBD, with EEN-and steroid-free remission rates at last follow-up of 39% and 24% in UC/IBD-U and CD, respectively. In this previously refractory cohort, among those who underwent evaluation, 15% and 17% had demonstrated mucosal healing and 30% and 0% achieved calprotectin < 100 mcg/g, respectively. Consistent with the finding in GEMINI 3, 3 there was a slower response rate in CD than in UC. The slower rate of response in CD as demonstrated in our study is a finding of potential clinical significance when selecting appropriate patients for vedolizumab therapy. Considering the refractory nature of our cohort, these data show promise for this newer class of biological therapy in paediatric UC, and to a lesser extent also in CD.
Our remission rate in CD is comparable to the paediatric cohort of Conrad et al. who report a Week 14 remission rate of 15%, 12 but significantly lower in both UC and CD remission rates than reported by Singh et al. [Week 14 remission of 76% and 42%, respectively]. When comparing with adult data, 1-year clinical remission rates in the GEMINI 1 and 2 were 18% and 12%, respectively, lower than those seen in our study. A more accurate comparison would be with the GEMINI 3 study of TNF-refractory CD patients, in whom 27% achieved clinical remission by Week 10. Adult real-world cohorts report Week 14 CFR rates between 19% and 31% for CD and 19-36% for UC, 4-10 comparable to our data. Consistent with our findings was the lack of serious adverse events associated with vedolizumab in either of these series. Nonetheless, Conrad et al. reported 29 adverse events in children, including upper respiratory tract infections, nausea, fatigue, headaches, nasopharyngitis, skin infections, and sinusitis. 12 Whereas GEMINI 1 revealed no difference in adverse events between vedolizumab and placebo, 1 GEMINI 2 demonstrated a higher incidence of nasopharyngitis with vedolizumab than with placebo [12.3% vs 8%]. 2 The adult US VICTORY consortium of 212 patients reported enteric infections (five per 100 patient-year follow-up [PYF]), sinopulmonary infections [4.4 per 100 PYF] and arthralgia [3.1 per 100 PYF], among other less common adverse events. 9 Other reallife cohorts report infections from 0% to 25%, nasopharyngitis 0-23%, arthralgia 2-20%, and one report of anaphylaxis and rash. [4] [5] [6] [7] [8] Pruritis as an adverse event of vedolizumab had not been previously reported.
Within the paediatric population, responses to IBD treatment differ between older children and those with early-onset or very early-onset IBD. 20 In our cohort dosing was based on adult recommended dose with non-standardised, weight-based modifications in younger children. Since children weighing less than 30 kg are best dosed by body surface area [BSA] , 21 until formal dosing guidance is available it is reasonable to dose children with the equivalent of 300 mg/1.73m 2 [ie 175 mg/BSA], and those over 40 kg as adults. Our cohort did not show superiority of combination therapy over monotherapy with vedolizumab; however, this analysis is limited by the small sample size and limited follow-up. This comparative analysis was not specifically presented in the two previous paediatric case series. Shelton et al. did not find any benefit of combination therapy over sole vedolizumab in their adult cohort, but noted that the sample size may have been too small to detect a difference. 4 Considering the small sample size and the lack of comparison group, we found that shortening infusion interval from 8 to 4 weeks led to improved effect in 3/7 [43%]. This is supported by recent pharmacokinetic data demonstrating significant correlation between higher vedolizumab drug levels and clinical response in IBD patients. [22] [23] [24] In our cohort we did not demonstrate any disease features associated with better response, including age at diagnosis, disease location or extent, or disease duration. However, this needs to be re-assessed in larger studies.
Our study is limited by its retrospective nature and hence a lack of standardised treatment regimens and concomitant therapies, as well as endoscopic evaluation in only some patients. Despite being the largest cohort to date, the cohort is still limited in size. Response rates are difficult to relate solely to vedolizumab effect, since variable use of induction corticosteroids and nutritional therapy obviously contribute to clinical response. Since vedolizumab in paediatric IBD is limited to off-label use, our cohort was represented entirely by patients failing conventional therapies. Previous anti-TNF failure may be associated with lower remission rates than anti-TNF naïve patients; however, results from studies assessing these differences are conflicting. 4, 8, 9, [25] [26] [27] Our study presents encouraging data that vedolizumab is safe and effective in paediatric UC, and to a lesser extent also in CD. Although it might seem that combination therapy is not required, a larger focused study is required to address this question with certainty. Clinicians should be aware of possible adverse events related to the upper respiratory and nasopharygeal regions with vedolizumab. We show preliminary data suggesting that shortening infusion interval to 4 weeks may improve effectiveness in some patients. The currently enrolling prospective multicentre VEDOKIDS cohort study will further define the role of vedolizumab in paediatric IBD and will provide trough drug monitoring data to predict the success and required dosing in children.
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